Inserm U987, UVSQ-Paris-Saclay University, Ambroise Pare Hospital, Boulogne-Billancourt, France.
Inserm U987, UVSQ-Paris-Saclay University, Ambroise Pare Hospital, Boulogne-Billancourt, France.
Br J Anaesth. 2023 Jul;131(1):79-92. doi: 10.1016/j.bja.2023.04.021. Epub 2023 May 18.
Over the past few decades, substantial advances have been made in neuropathic pain clinical research. An updated definition and classification have been agreed. Validated questionnaires have improved the detection and assessment of acute and chronic neuropathic pain; and newer neuropathic pain syndromes associated with COVID-19 have been described. The management of neuropathic pain has moved from empirical to evidence-based medicine. However, appropriately targeting current medications and the successful clinical development of drugs acting on new targets remain challenging. Innovative approaches to improving therapeutic strategies are required. These mainly encompass rational combination therapy, drug repurposing, non-pharmacological approaches (such as neurostimulation techniques), and personalised therapeutic management. This narrative review reports historical and current perspectives regarding the definitions, classification, assessment, and management of neuropathic pain and explores potential avenues for future research.
在过去的几十年中,神经病理性疼痛的临床研究取得了实质性的进展。已经达成了更新的定义和分类。经过验证的问卷提高了对急性和慢性神经病理性疼痛的检测和评估;并描述了与 COVID-19 相关的新型神经病理性疼痛综合征。神经病理性疼痛的治疗已经从经验医学转向循证医学。然而,针对当前药物进行适当靶向治疗以及成功开发针对新靶点的药物仍然具有挑战性。需要创新的方法来改善治疗策略。这些主要包括合理的联合治疗、药物再利用、非药物方法(如神经刺激技术)和个性化治疗管理。本综述报告了有关神经病理性疼痛的定义、分类、评估和管理的历史和当前观点,并探讨了未来研究的潜在途径。